Moritz Robert Edward Jr. has reported an acquisition of 236 shares in Northern Trust Corp, a significant move that raises his total ownership to 8,636 shares. This transaction, dated October 30, 2026, underscores Moritz's ongoing investment in the financial sector, which is marked by intense competition among banks.
Northern Trust Corp, known for its operations in the banking industry, is categorized under the SIC code for state commercial banks. The company is headquartered in Chicago, Illinois, and is publicly traded under the ticker symbol NTRS.
According to the recent SEC filing (accession number 0002033834-26-000023), the purchase was made at a price of $169.07 per share. Following this acquisition, Moritz holds a total of 8,636 shares, which includes 989 stock units that are convertible into shares of the corporation's common stock on a 1-for-1 basis.
This acquisition could have implications for Northern Trust's market position and investor sentiment. As Moritz is a director at the company, his actions may influence other shareholders and potential investors regarding the bank's future performance.
Details were not available in the SEC filing regarding any upcoming votes or additional filings related to this transaction.
Moritz Robert Edward Jr. is identified as a director of Northern Trust Corp, which may enhance his influence on corporate governance and strategic decisions within the company. His recent acquisition of shares reflects a commitment to the bank's long-term growth prospects.
The SEC filing also indicates that Moritz's transaction was categorized under the code 'P,' signifying a purchase of shares. The direct ownership nature of this transaction suggests that Moritz has a significant personal stake in the company's performance, which could affect investor confidence.
Furthermore, the filing does not provide any information regarding Moritz's previous transactions or the total number of shares he has acquired over time, nor does it mention any specific plans for future transactions or any potential conflicts of interest that may arise from his position as a director.
Read Next
van Houte Hans Reports Stock Transactions at Nurix Therapeutics
Hansen Gwenn Acquires and Sells Shares at Nurix Therapeutics
Drouillard Vincent Amends Filing to Correct Share Sale Details
Drouillard Vincent reports sale of 10,000 shares in AerCap
Gilead Sciences CEO Daniel O'Day Executes Multiple Stock Sales
Le Peuch Olivier Sells 25,000 Shares of SLB Limited





